Actinogen Medical Ltd has released a press release.
US FDA Feedback Enhances Alzheimers Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Launch of XanADu Phase II Clinical Trial
- Appendix 4D & Half Year Report
- R&D Rebate
- Update on the Biofuel Research Program
- Trials recommence on antibiotic project
Later from Actinogen Medical
- US Patent Granted-Further Extends Xanamem Protection
- Landmark Research on Excess Cortisol & Alzheimers Disease
- Appendix 4C & Commentary
- Announcement of non-renounceable rights issue
- Further results in bio-ethanol test program
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical